{"id":"W4381838960","doi":"10.1182/bloodadvances.2023010254","title":"Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Seagen; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Brentuximab vedotin; Internal medicine; Nivolumab; Neutropenia; Oncology; Adverse effect; Transplantation; Clinical endpoint; Confidence interval; Lymphoma; Surgery; Chemotherapy; CD30; Clinical trial; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001556323,0.0005198588,0.001182617,0.0006213849,0.0008969072,0.0008453163,0.000438761,0.0007293087,0.0008266325],"category_scores_gemma":[0.001117599,0.0002343929,0.001823137,0.0005670168,0.0003315737,0.0006650339,0.0003433542,0.00160704,0.000507942],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00093853,"about_ca_system_score_gemma":0.0005383939,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002801052,"about_ca_topic_score_gemma":0.002663513,"domain_scores_codex":[0.9994496,0.0001109391,0.00006367674,0.00009209027,0.0001256235,0.0001581871],"domain_scores_gemma":[0.9990345,0.000171749,0.0003343792,0.0001045249,0.0001410121,0.0002138542],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.04458421,0.01427176,0.6487751,0.0004072264,0.002928793,0.006588745,0.001454079,0.003176672,0.01708136,0.0001689388,0.004389651,0.2561735],"study_design_scores_gemma":[0.004340106,0.06928499,0.895759,0.0001322585,0.002716649,0.00709601,0.0004262975,0.003049521,0.007525506,0.0002477871,0.009318318,0.0001036377],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9922262,0.004102503,0.0005869972,0.0002076819,0.00003723148,0.0001418657,0.0005604543,0.00005991926,0.002077008],"genre_scores_gemma":[0.9958482,0.0009432659,0.0002388141,0.0004317931,0.0000599445,0.00006767779,0.001330849,0.00001044666,0.001068984],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002801052,"threshold_uncertainty_score":0.008230686,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0092442261172573,"score_gpt":0.241202458622175,"score_spread":0.2319582325049176,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}